Stéphanie Papin, PhD, is project leader of the Parkinson’s Disease Therapeutics and Imaging programs at AC Immune, programs aimed at identifying small molecules as PET imaging agents and disease-modifying therapeutics.  Dr Papin has worked at AC Immune since January 2011 and was the first biological scientist at AC immune involved in the Tau Imaging program now partnered with Piramal. The development and validation of assays to identify small molecules binding to alpha-synuclein and tau aggregates in human tissues, as well as small molecules interfering with alpha-synuclein and tau aggregation and toxicity has been the main focus of Dr Papin’s work over the last few years.

Prior to joining AC Immune, Dr. Papin worked in academic laboratories, on the molecular mechanisms involved in neurodegenerative diseases as well as auto-inflammatory disorders. She received her PhD in human genetics from the University of Paris, France, in 2003.